Clinical Trial Results:
A randomized double blind controlled proof of concept study of the efficacy and safety of Valcyte® as an add-on therapy in patients with malignant glioblastoma with successful surgical resection of at least 90 % of the initial tumor and CMV infection demonstrated histollogically and immunohistochemically.
Summary
|
|
EudraCT number |
2006-002022-29 |
Trial protocol |
SE |
Global completion date |
06 Jun 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Mar 2021
|
First version publication date |
03 Mar 2021
|
Other versions |
|
Summary report(s) |
Summary attachment_2006-002022-29 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.